HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CHM
CHM Rab escort protein
Chromosome X Β· Xq21.2
NCBI Gene: 1121Ensembl: ENSG00000188419.15HGNC: HGNC:1940UniProt: A8K545
115PubMed Papers
21Diseases
0Drugs
319Pathogenic Variants
FUNCTIONAL ROLE
Highly Constrained
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
Rab-protein geranylgeranyltransferase complexprotein geranylgeranylationprotein bindingsmall GTPase bindingchoroideremiaRetinal dystrophyretinitis pigmentosaeye disease
✦AI Summary

CHM encodes Rab escort protein-1 (REP-1), a crucial component of the Rab geranylgeranyltransferase complex responsible for protein prenylation and intracellular vesicle trafficking 1. REP-1 functions as the substrate-binding subunit that captures unprenylated Rab proteins and presents them to the catalytic components for geranylgeranyl transfer, enabling proper membrane targeting and vesicle-mediated transport. CHM mutations cause choroideremia, an X-linked chorioretinal dystrophy characterized by progressive degeneration of photoreceptors, retinal pigment epithelium, and choriocapillaris 21. The disease affects approximately 1 in 50,000-100,000 people, manifesting as night blindness in childhood that progresses to peripheral visual field loss and eventual complete blindness 2. Most pathogenic variants represent loss-of-function mutations, including large genomic deletions, insertions/deletions, nonsense variants, and splice site mutations, with a notable prevalence of C-to-T transitions at CpG dinucleotides 34. The high frequency of null mutations makes choroideremia particularly suitable for gene replacement therapy approaches, with ongoing clinical trials showing promise for treatment 31.

Sources cited
1
CHM encodes REP-1 protein responsible for Rab prenylation and vesicle trafficking, and causes choroideremia
PMID: 35341685
2
Choroideremia prevalence and clinical manifestations
PMID: 30578482
3
Mutation spectrum includes loss-of-function variants and ongoing gene therapy trials
PMID: 33538369
4
High frequency of C-to-T transitions at CpG sites and suitability for gene replacement therapy
PMID: 27820636
⚠Limited data available β€” This gene has 4 indexed publications. Summary and analysis may be incomplete.
Disease Associationsβ“˜21
choroideremiaOpen Targets
0.81Strong
Retinal dystrophyOpen Targets
0.57Moderate
retinitis pigmentosaOpen Targets
0.55Moderate
eye diseaseOpen Targets
0.37Weak
night blindnessOpen Targets
0.27Weak
Chorioretinal atrophyOpen Targets
0.27Weak
Abnormality of the eyeOpen Targets
0.26Weak
genetic disorderOpen Targets
0.20Weak
cancerOpen Targets
0.09Suggestive
choroidal dystrophy, central areolar, 1Open Targets
0.07Suggestive
temporal lobe epilepsyOpen Targets
0.07Suggestive
X-linked retinal dysplasiaOpen Targets
0.07Suggestive
age-related macular degenerationOpen Targets
0.07Suggestive
Familial exudative vitreoretinopathyOpen Targets
0.07Suggestive
Stargardt diseaseOpen Targets
0.07Suggestive
severe early-childhood-onset retinal dystrophyOpen Targets
0.06Suggestive
Familial drusenOpen Targets
0.06Suggestive
Cone rod dystrophyOpen Targets
0.06Suggestive
Leber congenital amaurosis 13Open Targets
0.06Suggestive
retinitis pigmentosa 87 with choroidal involvementOpen Targets
0.06Suggestive
ChoroideremiaUniProt
Pathogenic Variants319
NM_000390.4(CHM):c.1363del (p.Ala455fs)Pathogenic
Retinal dystrophy|not provided|CHM-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 455
NM_000390.4(CHM):c.1019C>A (p.Ser340Ter)Pathogenic
not provided|Choroideremia
β˜…β˜…β˜†β˜†2026β†’ Residue 340
NM_000390.4(CHM):c.1771-1G>APathogenic
not provided
β˜…β˜…β˜†β˜†2026
NM_000390.4(CHM):c.315_318del (p.Ser105Argfs)Pathogenic
not provided|Retinal dystrophy
β˜…β˜…β˜†β˜†2026β†’ Residue 105
NM_000390.4(CHM):c.1138C>T (p.Gln380Ter)Pathogenic
not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 380
NM_000390.4(CHM):c.1584_1587del (p.Val529fs)Pathogenic
Choroideremia|Retinal dystrophy|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 529
NM_000390.4(CHM):c.1511-1G>APathogenic
not provided|CHM-related disorder|Choroideremia
β˜…β˜…β˜†β˜†2025
NM_000390.4(CHM):c.116+1G>APathogenic
Choroideremia|Retinal dystrophy|not provided
β˜…β˜…β˜†β˜†2025
NM_000390.4(CHM):c.1166+1G>APathogenic
not provided|Choroideremia
β˜…β˜…β˜†β˜†2025
NM_000390.4(CHM):c.979C>T (p.Gln327Ter)Pathogenic
not provided|Retinal dystrophy|Choroideremia
β˜…β˜…β˜†β˜†2025β†’ Residue 327
NM_000390.4(CHM):c.941-1G>APathogenic
Choroideremia|not provided
β˜…β˜…β˜†β˜†2025
NM_000390.4(CHM):c.1186G>T (p.Gly396Ter)Pathogenic
Choroideremia|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 396
NM_000390.4(CHM):c.877C>T (p.Arg293Ter)Pathogenic
Choroideremia|not provided|Retinal dystrophy|Thyroid cancer, nonmedullary, 1
β˜…β˜…β˜†β˜†2025β†’ Residue 293
NM_000390.4(CHM):c.1663A>T (p.Arg555Ter)Pathogenic
not provided|Choroideremia
β˜…β˜…β˜†β˜†2025β†’ Residue 555
NM_000390.4(CHM):c.1520A>G (p.His507Arg)Likely pathogenic
Choroideremia
β˜…β˜…β˜†β˜†2025β†’ Residue 507
NM_000390.4(CHM):c.817C>T (p.Gln273Ter)Pathogenic
not provided|Retinal dystrophy
β˜…β˜…β˜†β˜†2025β†’ Residue 273
NM_000390.4(CHM):c.525_526del (p.Glu177fs)Pathogenic
not provided|Retinal dystrophy|Choroideremia
β˜…β˜…β˜†β˜†2025β†’ Residue 177
NM_000390.4(CHM):c.649_652del (p.Tyr217fs)Pathogenic
not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 217
NM_000390.4(CHM):c.1358_1359delinsG (p.Ile452_Ser453insTer)Pathogenic
Retinal dystrophy|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 452
NM_000390.4(CHM):c.757C>T (p.Arg253Ter)Pathogenic
not provided|Retinitis pigmentosa|Retinal dystrophy|CHM-related disorder|Choroideremia
β˜…β˜…β˜†β˜†2025β†’ Residue 253
View on ClinVar β†—
Related Genes
RAB5CProtein interaction99%RAB5AProtein interaction97%RAB8AProtein interaction94%RAB3AProtein interaction94%RAB27AProtein interaction93%RAB7BProtein interaction92%
Tissue Expression6 tissues
Heart
100%
Brain
95%
Ovary
54%
Lung
52%
Liver
40%
Bone Marrow
21%
Gene Interaction Network
Click a node to explore
CHMRAB5CRAB5ARAB8ARAB3ARAB27ARAB7B
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt P24386
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.35Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.20 [0.13–0.35]
RankingsWhere CHM stands among ~20K protein-coding genes
  • #4,107of 20,598
    Most Researched115 Β· top quartile
  • #189of 5,498
    Most Pathogenic Variants319 Β· top 5%
  • #1,514of 17,882
    Most Constrained (LOEUF)0.35 Β· top 10%
Genes detectedCHM
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
CHM mutation spectrum and disease: An update at the time of human therapeutic trials.
PMID: 33538369
Hum Mutat Β· 2021
1.00
2
Chinese herbal medicine-derived extracellular vesicles as novel biotherapeutic tools: present and future.
PMID: 39587576
J Transl Med Β· 2024
0.90
3
Molecular genetics β€Žcharacterization and homology modeling of the CHM gene mutation: A study on its association with choroideremia.
PMID: 29555028
Mutat Res Rev Mutat Res Β· 2018
0.80
4
X-linked Choroideremia.
PMID: 30578482
Adv Exp Med Biol Β· 2018
0.70
5
X-Linked Choroideremia.
PMID: 40736811
Adv Exp Med Biol Β· 2025
0.60